vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and PROCORE TECHNOLOGIES, INC. (PCOR). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $349.1M, roughly 1.4× PROCORE TECHNOLOGIES, INC.). CLOVER HEALTH INVESTMENTS, CORP. runs the higher net margin — -10.1% vs -10.8%, a 0.7% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 15.6%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs 10.8%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Procore Technologies is an American construction management software as a service company founded in 2002, with headquarters in Carpinteria, California. Procore hosts a platform to connect those involved in the construction industry on a global platform. The software allows for the creation of simplified workflows and displays a consolidated view of construction products that includes the tracking of tasks, management of project workflows, and scheduling.

CLOV vs PCOR — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.4× larger
CLOV
$487.7M
$349.1M
PCOR
Growing faster (revenue YoY)
CLOV
CLOV
+29.2% gap
CLOV
44.7%
15.6%
PCOR
Higher net margin
CLOV
CLOV
0.7% more per $
CLOV
-10.1%
-10.8%
PCOR
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
10.8%
PCOR

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CLOV
CLOV
PCOR
PCOR
Revenue
$487.7M
$349.1M
Net Profit
$-49.3M
$-37.6M
Gross Margin
80.1%
Operating Margin
-10.1%
7.6%
Net Margin
-10.1%
-10.8%
Revenue YoY
44.7%
15.6%
Net Profit YoY
-123.2%
39.6%
EPS (diluted)
$-0.25

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
PCOR
PCOR
Q1 26
$349.1M
Q4 25
$487.7M
$349.1M
Q3 25
$496.6M
$338.9M
Q2 25
$477.6M
$323.9M
Q1 25
$462.3M
$310.6M
Q4 24
$337.0M
$302.0M
Q3 24
$331.0M
$295.9M
Q2 24
$356.3M
$284.3M
Net Profit
CLOV
CLOV
PCOR
PCOR
Q1 26
$-37.6M
Q4 25
$-49.3M
$-37.6M
Q3 25
$-24.4M
$-9.1M
Q2 25
$-10.6M
$-21.1M
Q1 25
$-1.3M
$-33.0M
Q4 24
$-22.1M
$-62.3M
Q3 24
$-9.2M
$-26.4M
Q2 24
$7.4M
$-6.3M
Gross Margin
CLOV
CLOV
PCOR
PCOR
Q1 26
80.1%
Q4 25
80.1%
Q3 25
79.7%
Q2 25
79.1%
Q1 25
79.1%
Q4 24
81.2%
Q3 24
24.5%
81.4%
Q2 24
30.3%
83.1%
Operating Margin
CLOV
CLOV
PCOR
PCOR
Q1 26
7.6%
Q4 25
-10.1%
-12.3%
Q3 25
-4.9%
-4.4%
Q2 25
-2.2%
-9.3%
Q1 25
-0.3%
-11.7%
Q4 24
-6.4%
-21.9%
Q3 24
-2.7%
-12.3%
Q2 24
2.0%
-5.2%
Net Margin
CLOV
CLOV
PCOR
PCOR
Q1 26
-10.8%
Q4 25
-10.1%
-10.8%
Q3 25
-4.9%
-2.7%
Q2 25
-2.2%
-6.5%
Q1 25
-0.3%
-10.6%
Q4 24
-6.6%
-20.6%
Q3 24
-2.8%
-8.9%
Q2 24
2.1%
-2.2%
EPS (diluted)
CLOV
CLOV
PCOR
PCOR
Q1 26
$-0.25
Q4 25
$-0.25
Q3 25
$-0.06
Q2 25
$-0.14
Q1 25
$-0.22
Q4 24
$-0.42
Q3 24
$-0.18
Q2 24
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
PCOR
PCOR
Cash + ST InvestmentsLiquidity on hand
$78.3M
$480.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$1.3B
Total Assets
$541.0M
$2.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
PCOR
PCOR
Q1 26
$480.7M
Q4 25
$78.3M
$768.5M
Q3 25
$684.0M
Q2 25
$620.9M
Q1 25
$566.7M
Q4 24
$194.5M
$775.4M
Q3 24
$288.0M
$756.9M
Q2 24
$254.8M
$735.4M
Stockholders' Equity
CLOV
CLOV
PCOR
PCOR
Q1 26
$1.3B
Q4 25
$308.7M
$1.3B
Q3 25
$340.9M
$1.2B
Q2 25
$344.2M
$1.2B
Q1 25
$336.1M
$1.2B
Q4 24
$341.1M
$1.3B
Q3 24
$342.2M
$1.3B
Q2 24
$324.9M
$1.3B
Total Assets
CLOV
CLOV
PCOR
PCOR
Q1 26
$2.2B
Q4 25
$541.0M
$2.2B
Q3 25
$559.7M
$2.1B
Q2 25
$575.0M
$2.0B
Q1 25
$583.7M
$1.9B
Q4 24
$580.7M
$2.1B
Q3 24
$653.0M
$2.0B
Q2 24
$674.2M
$2.0B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
PCOR
PCOR
Operating Cash FlowLast quarter
$-66.9M
$113.5M
Free Cash FlowOCF − Capex
$-69.0M
FCF MarginFCF / Revenue
-14.1%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
PCOR
PCOR
Q1 26
$113.5M
Q4 25
$-66.9M
$114.9M
Q3 25
$12.1M
$88.5M
Q2 25
$5.4M
$30.8M
Q1 25
$-16.3M
$66.0M
Q4 24
$34.8M
$29.1M
Q3 24
$50.0M
$39.3M
Q2 24
$44.8M
$58.7M
Free Cash Flow
CLOV
CLOV
PCOR
PCOR
Q1 26
Q4 25
$-69.0M
$109.2M
Q3 25
$11.4M
$83.1M
Q2 25
$4.8M
$27.9M
Q1 25
$-16.5M
$62.0M
Q4 24
$33.3M
$17.4M
Q3 24
$49.6M
$35.7M
Q2 24
$44.4M
$56.8M
FCF Margin
CLOV
CLOV
PCOR
PCOR
Q1 26
Q4 25
-14.1%
31.3%
Q3 25
2.3%
24.5%
Q2 25
1.0%
8.6%
Q1 25
-3.6%
20.0%
Q4 24
9.9%
5.8%
Q3 24
15.0%
12.1%
Q2 24
12.5%
20.0%
Capex Intensity
CLOV
CLOV
PCOR
PCOR
Q1 26
Q4 25
0.4%
1.6%
Q3 25
0.1%
1.6%
Q2 25
0.1%
0.9%
Q1 25
0.0%
1.3%
Q4 24
0.5%
3.9%
Q3 24
0.1%
1.2%
Q2 24
0.1%
0.7%
Cash Conversion
CLOV
CLOV
PCOR
PCOR
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
6.04×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons